Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Janssen Obtains Approval of Anti-HIV Drug Prezista Tablets 600 mg
January 7, 2015
- Taiho Obtains Approval of Double-Bag Formulation of Zosyn
January 7, 2015
- NBI Receives Approval for SGLT-2 Inhibitor Jardiance
January 6, 2015
- Takeda to Terminate License Agreement with AMAG for Iron Deficiency Anemia Treatment Ferumoxytol
January 6, 2015
- Sumitomo Dainippon to Reorganize Production Bases to Create Efficient, Low-Cost Production System
January 6, 2015
- AnGes MG Changes Development Strategy for NF-κB Decoy Oligo
January 5, 2015
- Shin Nippon Biomedical Laboratories to Tie Up with US CRO for Clinical Development Services
January 5, 2015
- Opdivo Receives Accelerated Approval in US for Malignant Melanoma: BMS
January 5, 2015
- Bayer Yakuhin Files PAH Drug Iloprost for Approval
December 26, 2014
- Sumitomo Dainippon Aims to File Lurasidone in Japan in FY2015 following Favorable Asian PIII Study Results
December 26, 2014
- Chugai Wins First Round in Patent Infringement Lawsuit for Oxarol Ointment
December 26, 2014
- Otsuka Obtains Rights from ARIAD to Develop, Commercialize Ponatinib in Japan and Other Asian Countries
December 26, 2014
- Taiho Completes NDA Submission for Lonsurf in US
December 26, 2014
- Takeda Files NDA for Glatiramer Licensed from Teva for Relapse Prevention of Multiple Sclerosis
December 26, 2014
- Astellas Expands Scope of Collaboration with Cytokinetics in Skeletal Muscular Disease Field
December 25, 2014
- NDA for Selexipag Filed in US by Actelion: Nippon Shinyaku
December 25, 2014
- Fujifilm Completes Acquisition of Kalon Biotherapeutics
December 24, 2014
- AZ, Quintiles Create New Drug Development Team, Fusing Pharma’s Expertise with CRO’s Knowhow
December 24, 2014
- Ono Licenses Exclusive Worldwide Rights for BTK Inhibitor to Gilead Excluding East and South East Asia
December 22, 2014
- Chugai, Yakult File Xeloda, Elplat for Postoperative Adjuvant Chemotherapy for Gastric Cancer
December 22, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…